Key Takeaways
- Revenue missed the 10-15% target, growing 7.4%: Geopolitical headwinds in Europe and Q4 tariff uncertainty deferred export orders, while a 24% drop in API average selling price over two years absorbed the benefit of a 57% volume jump.
- The formulation pivot is accelerating: Finished dosage revenue grew 29% in Q4 and 21% over two years, far outpacing API's 3-4% growth, as the company shifts from B2B to B2C to capture 60-70% value addition instead of 30-40%.
- API prices are "almost at the bottom": China has liquidated its excess inventory and is returning to normal costing, but Indian customers have not yet accepted the resulting raw material price increases, compressing near-term margins.
- A first-in-class liver drug filing opens an option: Resmetirom, for non-alcoholic fatty liver, has been filed with DCGI with the API fully manufactured in-house; the company is now seeking global partners.
- What to watch next quarter: Whether the deferred U.S. and European export orders return, whether Indian customers begin accepting the Chinese raw material price pass-through, and the pace of the medical representative ramp-up toward the September 30 hiring deadline.
API: Volume Up, Price Down, and a Bottoming Call
- Volume-price divergence defined the year: API quantity sold rose 57% from 304 to 476 tons, but revenue grew only 19% because the average selling price fell 24% from ₹26,000/kg to ₹20,300/kg over two years. The capacity expansion absorbed what would otherwise have been a revenue decline.
- China's inventory dump is over: During FY22-23, Chinese producers built large inventories and then sold them at any cost. Management says that inventory has now been liquidated and Chinese vendors are returning to normal costing, though Indian customers still resist the price increases.
- India exposure is being deliberately reduced: India API revenue was cut from ₹320 cr to ₹292 cr because the domestic market is unprofitable when solely dependent on China import prices. The company prefers to sell into export markets where prices adjust more readily.
- Key molecules are rotating: Loratadine has matured. Growth is now coming from atorvastatin (up 80% in four years), rosuvastatin (up 4x), and fexofenadine (up 8x). New product contribution grew 65% in four years to ₹114 crores, now 12.3% of API revenue.
- Europe was the standout geography: The European market grew almost 40% last year, while the U.S. was flat at ₹152-154 cr as some shipments were delayed by tariff uncertainty. Total exports grew 26% over three years to ₹700 crores despite Russia-Ukraine, Israel-Gaza, and Iran disruptions.
Suri: "I think last 2 years were very interesting to note that China had collected lot of huge inventories during FY '22, '23. So they were sitting on the inventory. They had to sell up those inventories at any cost... But now they have liquidated everything. Now they are coming back with a normal costing."
Formulations & OTC: The B2C Pivot
- Finished dosage is the growth engine: Formulation revenue grew 21% over two years to ₹344 cr, with Q4 up 29%. Management expects formulation growth to stay higher than API growth going forward, driven by forward integration from API to tablets and capsules.
- The value-addition math is compelling: Selling API B2B captures only 30-40% value addition. Making the tablet or capsule and going to market lifts that to 60-70%, a structural margin opportunity as the mix shifts.
- The medical representative force is doubling immediately: The field force will expand from 200 to 400 this year, then to 750, then to 1,200 over three years. Appointments are targeted for completion by September 30, with the remainder of the year for training. Management assumes roughly ₹50 lakhs revenue per person in the first two to three years.
- New Rx products are launching: Empagliflozin launched after its April 2025 patent expiry. Apixaban, ticagrelor, and bempedoic acid have also been introduced. Over 30 new products have been developed in the formulation R&D pipeline, a data point disclosed for the first time.
- OTC and wellness brands are scaling from a small base: LightLife weight loss product is growing 30-40% month-on-month. The online division is growing 30-40% year-on-year. The nutrition portfolio, including whey protein and pre-workout products, sells through sports nutrition stores and gyms. All remain small in absolute terms.
Suri: "So instead of selling it to only B2B, where our value addition is only 30% to 40%. But if we make a tablet and capsule and go to market, then we get a better value-addition, maybe 60% to 70% value-addition."
Medical Devices: A Long Runway, Backed by Capacity
- The installed base is tiny relative to the addressable market: India has an estimated 21.2 crore potential diabetic patients, roughly 62% undiagnosed. Even taking only 40% of the live market, or 10 crore patients, the company has only 1.4 crore glucometer installations. Management says there are "miles to go."
- Capacity is expanding across the device portfolio: Glucometer capacity is rising from 25 lakh to 36 lakh meters, test strips from 42 crore to 60 crore strips per annum, and BP monitors from 9 lakh to 18 lakh. Backward integration is improving device margins.
- The Sync app provides a digital hook: Launched to track BP and sugar readings, the app reached 100,000 downloads in its first month and now has 1.31 lakh downloads, building a direct consumer data asset.
- International device expansion is underway: Products have launched in Thailand, Qatar, and Oman. Two to three more countries are targeted this year. U.S. market negotiations have started, with a launch on amazon.com planned for the next quarter.
Resmetirom and the Pipeline Optionality
- Resmetirom is a first-in-class opportunity: The drug targets non-alcoholic fatty liver disease. Morepen has developed and manufactured the API fully in-house and filed all documentation with CDSCO. This is the first time the company has approached DCGI for a drug approval. Mankind is also a contender; both have been permitted to conduct bioequivalence studies.
- The partnership door is open: The company has been approached by large Indian firms and is open to global partners, seeking "maximum mileage" from the product. Once written protocol approval is received, bioequivalence studies will begin.
- Other pipeline molecules are advancing: Baricitinib, tafamidis, bilastine, rupatadine, and cariprazine are under development or at pilot scale. Bempedoic acid has been launched with initial trial quantities shipped, though no commercial deals have closed yet; management expects meaningful numbers in the coming two to three quarters.
- Patent expiries provide a tailwind: The contribution from new molecules is expected to grow from ₹114 cr toward ₹150-200 cr, with the rate of growth accelerating due to the patent expiry calendar over the next two to three years.
Margins: Compressed Now, with a Mix-Shift Remedy
- Q4 profitability was weak, but the full year was better: Export orders for the U.S. and European markets were deferred, and one product had a large bulk order in the prior-year quarter that did not repeat. Lower exports pulled EBITDA down.
- API margins are under price pressure: Falling API selling prices have compressed EBITDA margins. Raw material price increases from China have not yet been accepted by the Indian market, making domestic API business unprofitable. The company says it will compromise on revenue for one to two months or quarters rather than sell below a certain level.
- The formulation and device mix offers structural margin relief: Finished dosage carries gross margins around 70%, versus 30-40% for API. Medical device margins are increasing due to volume growth and backward integration. As these segments grow faster than API, the blended margin should improve.
- The investment phase in formulations is over: The three-to-four-year period of building new teams and entering new territories for finished dosage and OTC is complete. That segment is now positive. Administrative expenses are being kept on a tight leash, and as revenue scales with Rx and OTC, a proportional decrease in expenses is expected.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Quarterly revenue run-rate | Every quarter should touch ₹500 crores | Ongoing target |
| Capacity completion | All 600 KL of API capacity installed (514 KL already done) | Within FY26 |
| Medical representative hiring | Double field force from 200 to 400; appointments completed | By September 30, 2025 |
| Medical representative ramp-up | Expand to 750, then 1,200 over three years | Over next 3 years |
| U.S. consumer launch | Launch medical devices on amazon.com | Next quarter |
| Resmetirom bioequivalence studies | Begin studies once written protocol approval received from CDSCO | Upon DCGI approval |
| Bempedoic acid commercial traction | Expect to deliver meaningful numbers | Coming 2-3 quarters |
| EBITDA and gross margin improvement | Both expected to improve as mix shifts toward formulations and devices | Fiscal '26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹470 cr, +10.1% YoY |
| FY25 revenue | ₹1,830 cr, +7.4% YoY |
| Pharma business revenue | ₹1,334 cr (FY25), +5.8% YoY; Q4 growth 8.5% |
| Medical devices revenue | ₹496 cr (FY25), +12% YoY; Q4 ₹103 cr, +15% YoY |
| EBITDA margin | 10.5% (FY25), +40 bps YoY; Q4 EBITDA declined |
| PAT growth | +22% (FY25) |
| Export share of API | 72.1% (FY25), up from 67% in FY24 |
| Export value | ₹700 cr (FY25), +26% over 3 years |
| API sales quantity | 476 tons (FY25), +57% vs FY23 |
| API average selling price | ₹20,300 per kg, down 24% in 2 years from ₹26,000 per kg |
| New molecule contribution to API | 12.3% (FY25), up from 8% in FY22; ₹114 cr revenue |
| Formulation revenue | ₹344 cr (FY25), +21% over 2 years; Q4 finished dosage +29% |
| Glucometers installed base | 1.42 cr, +21% YoY |
| Test strips sold | 41.4 cr strips (FY25) |
| Glucometer and strips revenue | ₹387 cr (FY25) |
| BP monitor revenue growth | +14% (FY25); units sold ~11 lakh, +12% |
| Medical devices EBITDA margin | 15% to 17% |
| U.S. exposure | 6% to 7% of total revenue |
| Capacity expansion target | 600 KL API capacity by FY26-end, from 314 KL; 514 KL installed |
| Medical representative target | 400 by Sep 2025, then 750, then 1,200; currently 200 |